News / Uncategorized
A massive deal around CRISPR genome editing technology…
A massive deal around CRISPR genome editing technology…
August 21, 2023
Early stage company Mammoth Biosciences just inked a $691 billion deal with Vertex Pharmaceuticals. This is a massive deal for the biotech startup. And it demonstrates just how valuable CRISPR genetic editing technology is within the industry. As a reminder, Mammoth Biosciences was cofounded by Jennifer Doudna. She is one of the original inventors of CRISPR technology.
And the company is pioneering in vivo CRISPR therapies for hard-to-treat diseases. For context, in vivo therapies are administered directly inside the patient. This is compared to an ex vivo therapy, where the patient’s cells are removed from the body, treated, and then returned to the patient’s body.
To tackle these difficult diseases, Mammoth uses very small enzymes that are capable of delivering the therapy to a specific tissue within the human body. The nuance here is that larger enzymes, such as the original CRISPR Cas-9 enzyme, are too big to reach these particular targets. And that’s exactly what Vertex is interested in with this deal. Vertex wants to develop therapies for two genetic diseases using Mammoth’s delivery enzymes. It is paying Mammoth $41 million upfront to get access.
And Vertex has agreed to pay up to $650 million more if these two therapies hit certain milestones. What’s more, Vertex will also pay Mammoth royalties on sales if these therapies are ultimately approved by the Food and Drug Administration (FDA). So this could amount to a $1 billion-plus deal for Mammoth Biosciences – even though Vertex will develop these therapies itself.
So this shows us how valuable CRISPR genetic editing technology is within the biotech industry. Needless to say, the Mammoth deal is very bullish for the best players in genetic editing. I expect a handful of acquisitions to happen within the next 12–18 months in this space.
Share this article:
More in Uncategorized:
Hedge funds and banks typically use multiple time frames for intraday trading
Hedge funds and banks typically use multiple time frames for intraday trading, as this allows them to gain a comprehensive...
![Trent Grinkmeyer in front of stock market with bull background](https://bestofusinvestors.com/uploads/2023/06/trent-e1687263019450-300x300.webp)
Trent Grinkmeyer
August 30, 2024
Nvidia Earnings Call: A Record Quarter with a Twist
Nvidia’s Q2 earnings call was a mixed bag, with the company reporting a record quarter but also revealing a drop...
![Kerry Grinkmeyer in a suit standing in front of a stock chart with a bull on it](https://bestofusinvestors.com/uploads/2023/07/kerry-300x300.webp)
Kerry Grinkmeyer
August 29, 2024
Nvidia Earnings: A Critical Moment for Big Tech
As we approach Nvidia’s earnings report, the tech world holds its breath. This isn’t just about one company’s performance; it’s...
![Trent Grinkmeyer in front of stock market with bull background](https://bestofusinvestors.com/uploads/2023/06/trent-e1687263019450-300x300.webp)
Trent Grinkmeyer
August 28, 2024
The Sleeping Giant: Why Intel is an Undervalued Stock
As the world’s largest semiconductor company, Intel (INTC) has long been a household name in the tech industry. However, despite...
![Kerry Grinkmeyer in a suit standing in front of a stock chart with a bull on it](https://bestofusinvestors.com/uploads/2023/07/kerry-300x300.webp)
Kerry Grinkmeyer
August 23, 2024
The Trillion Dollar Addiction...
The Trillion Dollar Addiction That Amazon, Google, Meta and Microsoft Will Be Selling Next Year As I discussed in my...
![Kerry Grinkmeyer in a suit standing in front of a stock chart with a bull on it](https://bestofusinvestors.com/uploads/2023/07/kerry-300x300.webp)
Kerry Grinkmeyer
August 19, 2024
What is an AI Agent? What Can It Do For You? Where Can You Get One?
As I discussed with my tribe during our recent stock talk, I’m excited to share with you the concept of...
A massive deal around CRISPR genome editing technology…
August 18, 2024